Guy Boivin is a professor in the Department of Microbiology-Immunology and Infectious Diseases of the Faculty of Medicine at Laval University. He holds the Canada Research Chair in Emerging Viruses and Antiviral Resistance, as well as a Foundation grant from the Canadian Institutes of Health Research (CIHR). He is also a co-principal investigator of major grants, such as the FPQIS (USD 12M), for the development of a new-generation influenza vaccine for the elderly. He is the author or co-author of 400 scientific publications and 350 presentations at various international conferences and symposia. He has also contributed to the creation of nine patents and is co-founder of the company Signia Therapeutics, specializing in the repositioning of drugs to counter viral respiratory infections. He is also the director of an NC3 laboratory that has been operational since 2020, which expands the various research projects to highly pathogenic respiratory viruses, such as avian influenza viruses (H5N1, H7N9) and other emerging respiratory viruses (SARS-CoV-2). His research program focuses on the diagnosis, pathogenesis and treatment of viral infections. He studies herpetic and respiratory viruses, including those causing the flu (including avian flu).
Guy Boivin is a professor in the Department of Microbiology-Immunology and Infectious Diseases of the Faculty of Medicine at Laval University. He holds the Canada Research Chair in Emerging Viruses and Antiviral Resistance, as well as a Foundation grant from the Canadian Institutes of Health Research (CIHR). He is also a co-principal investigator of major grants, such as the FPQIS (USD 12M), for the development of a new-generation influenza vaccine for the elderly. He is the author or co-author of 400 scientific publications and 350 presentations at various international conferences and symposia. He has also contributed to the creation of nine patents and is co-founder of the company Signia Therapeutics, specializing in the repositioning of drugs to counter viral respiratory infections. He is also the director of an NC3 laboratory that has been operational since 2020, which expands the various research projects to highly pathogenic respiratory viruses, such as avian influenza viruses (H5N1, H7N9) and other emerging respiratory viruses (SARS-CoV-2). His research program focuses on the diagnosis, pathogenesis and treatment of viral infections. He studies herpetic and respiratory viruses, including those causing the flu (including avian flu).